Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential nab-paclitaxel + gemcitabine followed by FOLFIRI.3 vs nab-paclitaxel + gemcitabine in first-line metastatic pancreatic adenocarcinoma
2014-004449-28Phase 2Completed
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Apr 2015
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of paclitaxel, gemcitabine, irinotecan, fluorouracil and folinic acid in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PDAC) (2 arms), sponsored by Fédération Francophone de Cancérologie Digestive. Primary endpoint: 6-month progression-free survival rate. Started Apr 2015; status: completed.
02
Drugs
paclitaxelgemcitabineirinotecanfluorouracilfolinic acid
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PDAC)
Beyond the preview
Go deeper on 2014-004449-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004449-28.